Dose-Independent Pharmacokinetics of a New Reversible Proton Pump Inhibitor, KR-60436, after Intravenous and Oral Administration to Rats: Gastrointestinal First-Pass Effect

Keeling, 1991, SK&F 96067 is a reversible, lumenally acting inhibitor of the gastric (H+/K+)-ATPase, Biochem Pharmacol, 42, 123, 10.1016/0006-2952(91)90690-7

Brown, 1990, Reversible inhibitors of the gastric (H+/K+)-ATPase. 1. 1-Aryl-4-methyl pyrrolo[3,2-c]quinolines as conformationally restrained analogues of 4-(arylamino) quinolines, J Med Chem, 33, 527, 10.1021/jm00164a010

Yu, 2002, HPLC analysis of a new reversible proton pump inhibitor, a dihydropyrroloquinoline derivative, in plasma, urine and tissue homogenates, J Liq Chromatogr Rel Technol, 25, 2687, 10.1081/JLC-120014385

Shim, 2000, Pharmacokinetics, stability, and blood partition of DA-8159, a new phosphodiesterase V inhibitor, Res Commun Mol Pathol Pharmacol, 108, 275

Lee, 1981, Pharmacokinetics of drugs in blood II. Unusual distribution and storage effect of furosemide, Res Commun Chem Pathol Pharmacol, 34, 17

Shim, 2000, Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique, Biopharm Drug Dispos, 21, 285, 10.1002/bdd.238

Kim, 1999, Pharmacokinetic changes of a new carbapenem, DA-1131, after intravenous administration to spontaneously hypertensive rats and deoxycorticosterone acetate-salt-induced hypertensive rats, Drug Metab Dispos, 27, 710

Litterst, 1975, Comparison of in vitro drug metabolism by lung, liver, and kidney of several common laboratory species, Drug Metab Dispos, 3, 259

Kim, 1993, Pharmacokinetics and pharmacodynamics of furosemide in protein–calorie malnutrition, J Pharmacokinet Biopharm, 21, 1, 10.1007/BF01061772

Kim, 1997, Liver and gastrointestinal first-pass effects of azosemide in rats, J Pharm Pharmacol, 49, 878, 10.1111/j.2042-7158.1997.tb06129.x

Xu, 1992, Kinetics of aluminum in rats. III: Effect of route of administration, J Pharm Sci, 81, 160, 10.1002/jps.2600810212

Yoon, 1998, Species differences in pharmacokinetics of a hepatoprotective agent, YH439, and its metabolites, M4, M5, and M7 after intravenous and oral administration to rats, rabbits, and dogs, Drug Metab Dispos, 26, 152

Gibaldi, 1982

Chiou, 1979, New calculation method for mean apparent drug volume of distribution and application to rational dosage regimen, J Pharm Sci, 68, 1067, 10.1002/jps.2600680843

Eatman, 1977, Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects, J Pharmacokinet Biopharm, 5, 481, 10.1007/BF01061729

Chiou, 1980, New calculation method of mean total body clearance of drugs and its application to dosage regimens, J Pharm Sci, 69, 90, 10.1002/jps.2600690125

Kim, 1999, Stability, blood partition, and plasma protein binding of ipriflavone, an isoflavone derivative, Biopharm Drug Dispos, 20, 355, 10.1002/(SICI)1099-081X(199910)20:7<355::AID-BDD197>3.0.CO;2-X

Prandota, 1975, Furosemide binding to human albumin and plasma of nephritic syndrome, Clin Pharmacol Ther, 17, 159, 10.1002/cpt1975172159

Mackchan, 1992, Influence of protein binding and use of unbound (free) drug concentration, 5-1

Lee, 1995, Factors influencing the protein binding of YH-439 using an equilibrium dialysis technique, a new hepatoprotective agent, Biopharm Drug Dispos, 16, 775, 10.1002/bdd.2510160907

Davies, 1993, Physiological parameters in laboratory animals and humans, Pharm Res, 10, 1093, 10.1023/A:1018943613122

Mitruka, 1982

Lee, 1983, Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism, J Pharmacokinet Biopharm, 11, 623, 10.1007/BF01059061

Kim, 2000, Gastrointestinal first-pass effect of furosemide in rats, J Pharm Pharmacol, 152, 1337, 10.1211/0022357001777487

Han, 1999, Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: Hepatic and gastric first-pass effects, Drug Metab Dispos, 27, 221

Kim, 2001, Dose-dependent pharmacokinetics of a new irreversible proton pump inhibitor, DBM-819, in rats: Hepatic and gastric first-pass effect, Biopharm Drug Dispos, 22, 119, 10.1002/bdd.264

Kim, 1999, Gastrointestinal first-pass effect of YJA-20379-8, a new reversible proton pump inhibitor, in rats, J Pharm Pharmacol, 51, 1031, 10.1211/0022357991773519

Huang, 1981, Oral absorption and presystemic first-pass effect of chlorpheniramine in rabbits, J Pharmacokinet Biopharm, 9, 725, 10.1007/BF01070903

Haber, 1996, Metabolism of alcohol by human gastric cells: Relation to first-pass metabolism, Gastroenterology, 111, 863, 10.1016/S0016-5085(96)70054-9

Kim, 1998, Hepatic and intestinal first-pass effects of a new hepatoprotective agent, YH439, in rats, Res Commun Mol Pathol Pharmacol, 102, 125

Kim, 2002, Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats: Hepatic and intestinal first-pass effects, Life Sci, 70, 1299, 10.1016/S0024-3205(01)01508-9

Kim, 2000, Intestinal first-pass effect of bumetanide in rats, Int J Pharm, 194, 193, 10.1016/S0378-5173(99)00360-9

Lee, 2003, Dose-independent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543, after intravenous and oral administration to rats: Hepatic and intestinal first-pass effects, J Pharm Sci, 92, 190, 10.1002/jps.10289

Kim, 2003, Dose-independent pharmacokinetics of a candidate for diabetic neuropathy, SR-4668, after intravenous and oral administration to rats: intestinal first-pass effect, J Pharm Sci, 92, 1112, 10.1002/jps.10376

Paine, 1996, First-pass metabolism of midazolam by the human intestine, Clin Pharmacol Ther, 60, 14, 10.1016/S0009-9236(96)90162-9

Fizsimmons, 1997, Selective biotransformation of the human immunodeficiency virus protease inhibitor, saquinavir by human small intestine cytochrome P4503A4: Potential contribution to high first-pass metabolism, Drug Metab Dispos, 25, 256